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Supplementary Table S1: Details of the Trypanosoma cruzi used in this study 
 
T. cruzi DTU Original host1-4 Geographical 
origin2,4-9 
Genotyping Methods 




TcSC5D single locus amplification and 
sequencing10-18 
Y II Human São Paulo,  
Brazil 
TcSC5D single locus amplification and 
sequencing11,19-21 
ARMA13 cl1 III Armadillo 
Dasypus novemcinctus 
Campo Lorro,  
Paraguay 
Multilocus microsatellite genotyping4,22 
Large Subunit rDNA PCR product size 
polymorphism & PCR- Restriction 
Fragment Length Polymorphism (PCR-
RFLP) assay23,24 
Multilocus Sequence Typing (MLST)25  
ERA cl2 IV Human Anzoátegui,  
Venezuela 
Multilocus microsatellite genotyping4 
Large Subunit rDNA PCR product size 
polymorphism & PCR-restriction 
fragment length polymorphism (PCR-
RFLP) assay24 
92-80 cl2 V Human Santa Cruz,  
Bolivia 
Multilocus microsatellite genotyping4 
Large Subunit rDNA PCR product size 
polymorphism & PCR-restriction 
fragment length polymorphism (PCR-
RFLP) assay24 
Multilocus sequence typing (MLST)25  
CL Brener VI Triatoma infestans Rio Grande do 
Sul,  
Brazil 
rRNA & miniexon gene sequence26 
Multilocus microsatellite genotyping4 
Large Subunit rDNA PCR product size 
polymorphism & PCR-restriction 
fragment length polymorphism (PCR-
RFLP) assay24 
Multilocus sequence typing (MLST)25  
TcSC5D single locus amplification and 
sequencing11 
Tulahuen VI Human Tulahuen,  
Chile 




(Previous page) Supplementary Figure S1. Compound activity measurements based on raw 
datat of the average number of parasites per infected cell. Experimental conditions and datasets 
are the same of manuscript’s Figure 1. Each dose-response curve represents one strain or clone as 
follows: Dm28c, purple; Y, red; ARMA13 cl1, orange; ERA cl2, light green; 92-80 cl2, light blue; 
CL Brener, dark blue; and Tulahuen, dark green. The X-axis shows log of compound molar 
concentrations (M) and Y-axis shows the non-normalized activity (raw data) based on the 
measurement average number of parasites per infected cell. Data refers to mean values of at least two 
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